MedPath

The Vanderbilt University

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2
Terminated
Conditions
Hormone-sensitive Metastatic Breast Cancer
Interventions
First Posted Date
2010-09-20
Last Posted Date
2012-09-11
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
11
Registration Number
NCT01205685
Locations
🇺🇸

Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

Terminated
Conditions
Lung Cancer
Interventions
Other: internet-based protocol and physician referral
First Posted Date
2010-06-10
Last Posted Date
2017-04-25
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
88
Registration Number
NCT01141218
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Terminated
Conditions
Breast Cancer
Cardiovascular Complications
Colorectal Cancer
Fallopian Tube Cancer
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: laboratory biomarker analysis
Other: questionnaire administration
First Posted Date
2010-03-31
Last Posted Date
2012-02-27
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
8
Registration Number
NCT01096381
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel

Terminated
Conditions
Arthralgia
Pain
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: assessment of therapy complications
First Posted Date
2010-03-31
Last Posted Date
2013-04-04
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
5
Registration Number
NCT01096407
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
Other: laboratory biomarker analysis
First Posted Date
2009-12-14
Last Posted Date
2018-08-31
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
55
Registration Number
NCT01031446
Locations
🇺🇸

Erlanger Cancer Center at Erlanger Hospital - Baroness, Chattanooga, Tennessee, United States

🇺🇸

West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States

🇺🇸

Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 1 locations

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2
Withdrawn
Conditions
Breast Cancer
Interventions
First Posted Date
2009-11-13
Last Posted Date
2013-05-23
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Registration Number
NCT01013506

Opioids Titration in Hospice Patients

Withdrawn
Conditions
Pain
Solid Tumor
Interventions
Behavioral: telephone-based intervention
Other: communication intervention
Other: intervention by caregiver
Other: medical chart review
Other: survey administration
Procedure: end-of-life treatment/management
Procedure: pain therapy
Procedure: psychosocial assessment and care
First Posted Date
2009-11-04
Last Posted Date
2013-04-02
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Registration Number
NCT01007422

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Phase 1
Completed
Conditions
Liver Cancer
Gallbladder Cancer
Pancreatic Cancer
Small Intestine Cancer
Extrahepatic Bile Duct Cancer
Periampullary Adenocarcinoma
Interventions
First Posted Date
2009-10-01
Last Posted Date
2017-07-02
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
28
Registration Number
NCT00987766
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery

Not Applicable
Terminated
Conditions
Breast Cancer
Interventions
Other: laboratory biomarker analysis
First Posted Date
2009-09-25
Last Posted Date
2024-02-01
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
5
Registration Number
NCT00984490
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

🇺🇸

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
First Posted Date
2009-09-25
Last Posted Date
2014-03-12
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
50
Registration Number
NCT00984542
Locations
🇺🇸

Hardin Memorial Hosptial, Elizabethtown, Kentucky, United States

🇺🇸

Jackson-Madison County Hospital, Jackson, Tennessee, United States

🇺🇸

Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath